Magali Haas
Chief Medical Officer Psilera Bioscience
Seminars
Thursday 17th September 2026
Panel Discussion: To What Degree Does Neuroplasticity Underpin Psychedelics Efficacy?
9:00 am
- What do we mean by neuroplasticity, and why has it become central to next-generation neuropsychiatric drug development?
- To what extent does neuroplasticity drive therapeutic efficacy, and can it be separated from hallucinogenic effects?
- How are researchers measuring neuroplasticity across preclinical and clinical settings?
- What biomarkers and technologies could help establish objective measures of neuroplastic change in patients?
Thursday 17th September 2026
Roundtable Discussion: Clinical Trial Design for Neuropsychiatry: Driving Efficient Early Development & Decision Making
1:30 pm
- How can clinical trial designs be adapted to address the complexity and heterogeneity of neuropsychiatric disorders?
- Strategies for selecting endpoints, patient populations, and enrichment approaches that maximize the likelihood of detecting meaningful clinical signals
- Balancing speed, cost, and scientific rigor when designing early-phase neuropsychiatry studies with limited resources
- Lessons learned from recent neuropsychiatric programs on improving recruitment, reducing trial burden, and generating actionable data
- Opportunities to leverage translational insights, biomarkers, and innovative study designs to de-risk development and accelerate progression into later-stage trials
